Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor EntitiesNader Hirmas, Wolfgang P. Fendler, Martin Glas et al.|Journal of Nuclear Medicine|2022Cited by 68
Superior Tumor Detection for<sup>68</sup>Ga-FAPI-46 Versus<sup>18</sup>F-FDG PET/CT and Conventional CT in Patients with CholangiocarcinomaKim M. Pabst, Wolfgang P. Fendler, Marija Trajkovic‐Arsic et al.|Journal of Nuclear Medicine|2023Cited by 63
<sup>68</sup>Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical TherapyHelena Lanzafame, Wolfgang P. Fendler, Ilektra A. Mavroeidi et al.|Journal of Nuclear Medicine|2024Cited by 36
<sup>68</sup>Ga-Labeled Fibroblast Activation Protein Inhibitor (<sup>68</sup>Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the<sup>68</sup>Ga-FAPI PET Observational TrialLukas Kessler, Jens T. Siveke, Nader Hirmas et al.|Journal of Nuclear Medicine|2023Cited by 34
Diagnostic Accuracy of<sup>68</sup>Ga-FAPI Versus<sup>18</sup>F-FDG PET in Patients with Various MalignanciesNader Hirmas, Wolfgang P. Fendler, Rainer Hamacher et al.|Journal of Nuclear Medicine|2024Cited by 31